Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.
US-based healthcare firm Nexus Pharmaceuticals is set to construct a new sterile injectable manufacturing facility in Wisconsin, US.
Bristol-Myers Squibb (BMS) is planning to divest Celgene’s psoriasis drug Otezla (apremilast), in a bid to expedite the process of merger with Celgene.
Gamida Cell and Lonza announced that the companies have entered into a strategic manufacturing agreement.
WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that it has entered into a strategic partnership letter of intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market.
Catalent has wrapped up its $1.2bn acquisition of Maryland-based gene therapy contract development and manufacturing organisation (CDMO) Paragon Bioservices.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GlaxoSmithKline plc (NYSE: GSK) for approximately €90 million in cash.
Pfizer has announced the opening of a new 175,000 square-foot manufacturing facility in Andover, Massachusetts.
Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer.
British drugmaker GlaxoSmithKline (GSK) is set to invest $100m to expand long-term vaccine manufacturing capabilities at its Hamilton facility in Montana, US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.